Dovec, patch medications only work when drugs have smaller molecules, which is not the case with semaglutide
It is being studied in clinical trials, and Lilly has reported positive Phase 3 topline results, but investigational results are not the same as FDA approval
Insulin and IGF-1 signaling GLP-1 medications improve insulin sensitivity, which is one of their major metabolic benefits
Two-thirds of lost weight typically returns within a year of stopping
Orforglipron, the easier-to-use alternative to injectable weight-loss and diabetes medications, is a promising new tool with improved convenience for providers and patients
These may occur with or without pain, and, as with other injection site reactions, usually go away on their own within a few days